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ABSTRACT 
Pulmonary arterial hypertension (PAH) is an incurable cardiovascular disease 
characterized by high blood pressure in the arteries leading from the heart to the lungs. 
Over 2 million people in the United States are diagnosed with PAH annually and the 
typical survival rate is only 3 years after diagnosis (Archer, Weir et al. 2010). Current 
treatments are insufficient because of limited bioavailability, toxicity, and cost 
associated with approved therapeutics. Aerosol delivery of drugs is an attractive 
approach to treat respiratory diseases because it increases localized drug concentration 
while reducing systemic side effects. Dry powder inhalers (DPIs) allow for increased 
physicochemical stability of drugs and increased patient compliance. Dry powder 
aerosols can be easily designed to meet certain specifications including size, 
morphology, and crystallinity via spray drying (Meenach, Vogt et al. 2013). 
Tacrolimus (TAC) is a drug that has recently been found to be useful in treating PAH 
(Spiekerkoetter, Tian et al. 2013). TAC interacts with bone morphogenic protein 
receptor type II (BMPR2), which is often mutated or underexpressed in patients with 
PAH (Humbert, Morrell et al. 2004). The expression of BMPR2 inhibits vascular 
remodeling, thereby reducing blood pressure. Unfortunately, TAC is poorly water-
soluble and toxic when delivered systemically over a long period of time, this driving 
the need for improved formulations and delivery of the compound. 
Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylglycerol 
(DPPG) are phospholipids naturally present in the lungs that act as a biodegradable 
surfactant when used in a 3:1 ratio as an excipient in dry powder microparticles. DPPC 
and DPPG can improve particle migration in the lungs and increase lung residence 
  
time (Hadinoto, Phanapavudhikul et al. 2007). I hypothesize that targeting the delivery 
of tacrolimus to the lungs using phospholipid-based dry powder aerosol microparticles 
will result in increased localized drug concentrations, improving the treatment of 
pulmonary arterial hypertension and decreasing the severity of side effects 
experienced by patients. 
In this study, phospholipid-based aerosol microparticles were developed via spray 
drying. These particles were shown to be smooth and spherical in size, ranging from 
1-3 µm in diameter. The microparticles exhibited thermal stability and were found to 
be amorphous after spray drying. Water content in the microparticles was under 10%, 
which will allow successful aerosol dispersion and long-term storage stability. In vitro 
aerosol dispersion showed that the microparticles could successfully deposit in the 
deep lung, as they exhibited favorable aerodynamic diameters and high fine particle 
fractions. In vitro dose-response analysis showed that TAC is nontoxic in the low 
concentrations that would be delivered to the lungs. Overall, this work shows that 
tacrolimus-loaded phospholipid-based microparticles can be successfully created with 
optimal physicochemical characteristics. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background and Treatment of Pulmonary Arterial Hypertension 
Pulmonary arterial hypertension (PAH) is a chronic, incurable cardiovascular 
disease with a 15% annual mortality rate. PAH involves an increase in pulmonary 
vascular resistance due to pulmonary arterial obstructions and can eventually lead to 
right ventricular failure and ultimately death. Annually, 2.4 new cases are diagnosed 
per million people (Archer, Weir et al. 2010) and there is a mean life expectancy of 3 
years after diagnosis with PAH (Saigal, Ng et al. 2013). It is likely that the worldwide 
impact of pulmonary arterial hypertension is much more widespread than current 
diagnoses suggest due to the difficulty of accurately diagnosing patients. 
Vasoconstriction, remodeling of the pulmonary vessel wall, and thrombosis cause 
increased pulmonary vascular resistance in PAH patients. The characteristic 
pathogenesis of PAH is pulmonary arterial obstruction caused by vascular 
proliferation and remodeling, which occurs in all layers of the vessel wall (Humbert, 
Morrell et al. 2004). In Figure 1, the heart and lungs of a healthy adult are compared 
to those of an adult with PAH. Pulmonary arterial hypertension is defined by a mean 
pulmonary artery pressure of 25 mm Hg at rest and 30 mm Hg while exercising 
(Rosenblum 2010). PAH can be idiopathic, familial, related to connective tissue 
disease, or caused by drug or toxin exposure. Idiopathic, familial, and anorexigen-
associated PAH have similar clinical, functional, and hemodynamic characteristics 
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(Humbert, Sitbon et al. 2010). Features of PAH include intimal fibrosis, distal 
localization and proliferation of vascular smooth muscle, and pulmonary arterial 
occlusion. PAH is also associated with alterations in the rates of cellular proliferation 
and apoptosis, resulting in thickened arteries. Severe end stages of PAH often result in 
plexiform lesions due to disorganized endothelial cell proliferation (Humbert, Morrell 
et al. 2004). Hormones, growth factors, neurotransmitters, and environmental stresses 
can promote the development of PAH. One of the primary causes of PAH progression 
is an imbalance of the neurochemical mediators that help maintain the vascular tones 
of pulmonary arteries (Gupta, Rawat et al. 2010). The prostacyclin, nitric oxide, ion 
channels, endothelin-1, and serotonin pathways have been connected with PAH.  
Bone morphogenic protein receptor type II (BMPR2) is an active serine/threonine 
kinase receptor, which signals via the formation of heterocomplexes in response to 
ligands (Humbert, Morrell et al. 2004). BMPR2 plays a large role in familial and 
idiopathic PAH, but is not likely to be the root cause of PAH. Genetic and 
environmental factors are thought to play a larger role (Hong, Lee et al. 2008). 
BMPR2 gene mutations are found in more than 70% of cases of familial PAH and 
10% to 40% of apparently sporadic or anorexigen-associated PAH (Humbert, Sitbon 
et al. 2010). In cases of PAH without a BMPR2 mutation, BMPR2 expression is still 
significantly reduced (Humbert, Morrell et al. 2004). Improving the signaling of 
BMPR2 reduces damaging vascular remodeling and can potentially improve patient 
symptoms and outcomes (Spiekerkoetter, Tian et al. 2013). 
Current therapies for the treatment of pulmonary arterial hypertension include 
prostanoids, endothelin receptor blockers, phosphodiesterase type 5 (PDE5) inhibitors, 
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and soluble guanylate cyclase (SGC) stimulators that are typically delivered orally or 
intravenously. These therapeutics are often paired with anticoagulation and diuretic 
drugs due to the risk of thrombosis and edema associated with these treatments 
(Archer, Weir et al. 2010). Prostanoids, such as Flolan® and Remodulin®, are often 
used to reduce inflammation and vasoconstriction by targeting the prostacyclin 
pathway. These compounds inhibit cells in the middle of blood vessels from growing 
into lesions (Feldman). Prostanoids are typically considered the best treatment option, 
but the dosage forms used limit patient compliance and cause negative systemic side 
effects (Saigal, Ng et al. 2013). Endothelin receptor blockers, such as Letairis®, inhibit 
the endothelin pathway, which normally causes vasoconstriction by promoting the 
growth of cells in the middle of blood vessels resulting in the formation of lesions.  
PDE5 inhibitors and SGC stimulators both target the nitric oxide pathway. PDE5 
inhibitors, such as Revatio®, decrease the effect of PDE5, thereby increasing the 
concentration of nitric oxide in the blood. SGC stimulators, such as Adempas®, 
stimulate SGC in cells, causing an increased production of cyclic GMP, causing the 
pulmonary arteries to relax (Feldman). These treatments are highly expensive and 
difficult to deliver due to their limited bioavailability and toxicity of the drugs. 
Frequent dosing of these drugs is required because they have short half-lives. In 
addition, current therapies do not inhibit remodeling and patients are often required to 
receive heart and lung transplantations to increase their chances of survival 
(Spiekerkoetter, Tian et al. 2013).  Unfortunately, the progression of PAH and its 
treatments are primarily based on assessments of exercise performance, quality of life, 
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time to clinical deterioration, and physiological performance because lung tissue for 
diagnosis is difficult to obtain other than upon autopsy (Stacher, Graham et al. 2012).  
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Figure 1. Comparison of the physiological characteristics of a healthy heart and a 
heart with pulmonary hypertension from Nationwide Children’s Hospital. 
http://www.nationwidechildrens.org/pulmonary-hypertension 
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The limited bioavailability of current PAH therapeutics and their associated toxicity 
results in the need for more sophisticated formulations to aid in patient compliance 
and health. 
 
1.2 Aerosolized Therapeutics Produced via Spray Drying 
Aerosols are a common method used in treating a variety of pulmonary diseases 
because they allow for a faster onset of action, avoid the first-pass metabolism of the 
liver, which removes the drug from the body before it can reach the target organ, and 
result in low systemic drug concentrations. The lungs are an attractive approach for 
drug delivery because they are highly permeable and have a large surface area (35-140 
m2), allowing for higher bioavailability within the lungs (Shoyele and Cawthorne 
2006). In addition, they have an elevated blood flow of 5 L/min (Bosquillon, Lombry 
et al. 2001). The lungs have a small fraction of drug-metabolizing and efflux 
transporter activity compared to the gut and liver, resulting in drugs delivered through 
the lungs producing fewer complex metabolites, thereby increasing drug efficacy 
(Patton, Fishburn et al. 2004).  
The bronchial airways in human lungs have pseudostratified, ciliated, mucus-
producing cells, covered with approximately 8 µm of mucus (Haghi, Traini et al. 
2012). Particles that are delivered to the lungs as aerosols can produce a concentration 
gradient, causing the particles to undergo dissolution and solute transport across lung 
mucus and epithelium (Grainger, Greenwell et al. 2009). The rate of absorption in the 
lungs can improve pharmacokinetic profiles both locally in the lungs and systemically 
throughout the body (Forbes and Ehrhardt 2005). Targeted delivery to the lungs can be 
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enhanced by using microparticles as they can effectively deposit in the lungs by 
physical sedimentation (Li and Mansour 2011). Nebulizers, pressurized metered doze 
inhalers (pMDIs), soft-mist inhalers (SMIs), and dry powder inhalers (DPIs) are 
among the most frequently used aerosol delivery devices. Nebulizers are large and 
need to be used frequently for long periods of time and pMDIs require a propellant, 
causing these methods to be inconvenient to patients (Suarez and Hickey 2000). DPIs 
are beneficial because they allow for the delivery of particles designed with specific 
characteristics (particle size, drug loading, etc.) and the resulting dry powder particles 
and DPIs provide improved long-term chemical and physical stability (Meenach, Vogt 
et al. 2013). DPIs are also advantageous because they are propellant-free, portable, 
easy to operate, and inexpensive (Bosquillon, Lombry et al. 2001). They allow for 
effective, targeted delivery of drugs to the respiratory tract to treat a variety of 
pulmonary diseases. Formulations of dry powder particles delivered via DPIs typically 
consist of an active pharmaceutical ingredient (API) and excipient to improve stability 
and aerosolization (Guillon, Montharu et al. 2012). 
Efficient drug delivery to the lungs using a dry powder inhaler depends on the 
inhaler device, powder formulation, and inhalation maneuver (Kaialy, Alhalaweh et al. 
2011). The design specifications necessary for successful implementation in DPIs can 
easily be met by using advanced spray drying techniques of therapeutics and 
excipients for form dry powder aerosol particles. Spray drying is a high-throughput 
pharmaceutical particle engineering technique that efficiently produces respirable dry 
particles. Spray drying can enable facile control of the size, surface morphology, and 
shape of spray-dried particles by altering component concentrations, drying 
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temperature, pump rate, and gas flow of the spray-dryer (Iskandar, Gradon et al. 2003, 
Hoe, Ivey et al. 2014). There are four steps in a typical spray drying process as seen in 
Figure 2. First, the feed solution is atomized into a spray, followed by spray-air 
contact (step two). The sprayed droplets are dried at an elevated temperature (step 
three) and then the dried particles are separated from the air in a collection vial (step 
four) (Chow, Tong et al. 2007). Particle size and morphology play a large role in drug 
delivery (Chow, Tong et al. 2007). Optimally sized particles are within 1 to 5 µm for 
effective whole-lung deposition (Meenach 2014). Particles below 5 µm can be easily 
deposited into the smaller airways, whereas submicron particles will be exhaled 
(Chow, Tong et al. 2007). Choosing the correct feed solution when spray-drying 
poorly water soluble drugs is extremely important (Paudel, Worku et al. 2013). Using 
an organic feed solution can help achieve smaller sized particles with a lower water 
content (Li and Mansour 2011). Spray drying also increases the storage stability of 
particles due to the reduction in water content (Ré 2006). The short half-lives of drugs 
can be improved by developing spray-dried microparticles encapsulated in excipients 
such as lipids or polymers (Saigal, Ng et al. 2013). 
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Figure 2. The main stages involved in the spray-drying process (Ré 2006). 
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Figure 3. Percent deposition in the different sections of the lungs based on 
aerodynamic diameter (Laube, Janssens et al. 2011).  
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1.3 Tacrolimus  
Tacrolimus (TAC), first commercialized as Prograf® in 1990, is a poorly water-
soluble immunosuppressive agent derived from the fungus Streptomyces tsukubaensis 
(Cho 2014). Normally delivered intravenously or orally, in which it has poor 
bioavailability, TAC is typically used in the prevention of organ rejection after 
transplantations as an immunosuppressive agent (Gao, Sun et al. 2012). The aqueous 
solubility of tacrolimus is low, at 1-2 µg/mL, resulting in in challenges in dosage 
formulations (Park, Ryu et al. 2009). When delivered systemically for a prolonged 
period of time, TAC causes adverse side effects such as nephrotoxicity, the onset of 
diabetes mellitus, an increased risk of opportunistic infections, and neurotoxicity. In 
mild cases of neurotoxicity, the patient experiences headaches and tremors, but 
patients can experience seizures and delirium in more severe cases (Shin, Cho et al. 
2010). TAC has a narrow therapeutic index, making it necessary to closely monitor 
patients for toxicity. Severe side effects have been shown to occur at blood 
concentrations greater than 50 ng/mL (Watts, Peters et al. 2011). The target trough 
range of tacrolimus in the bloodstream is 5-20 µg/L, which requires careful and 
invasive monitoring (Sallustio, Noll et al. 2011). By targeting the delivery of TAC to 
the lung, the systemic concentration of the drug will be greatly reduced while 
increasing local pulmonary drug concentrations and therapeutic levels. Nebulized 
TAC has already been shown to improve the response of a lung transplant patient 
while substantially reducing side effects (Hayes, Zwischenberger et al. 2010). Blood 
levels have been found to remain low after the aerosolization of tacrolimus, reaching 
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1.6 ng/mL after twelve hours. (Schrepfer, Deuse et al. 2007). Because of this, patients 
will not have to be monitored as closely for systemic levels of TAC. 
TAC has been found to be effective in the treatment of pulmonary arterial 
hypertension. As mentioned previously, TAC induces the signaling of bone 
morphogenic protein receptor type II (BMPR2) in endothelial cells, which has been 
found to be dysfunctional in the pathogenesis of pulmonary arterial hypertension by 
inhibiting vascular remodeling (Spiekerkoetter, Tian et al. 2013). The chemical 
structure of tacrolimus can be seen in Figure 4. 
 
1.4 Phospholipid Excipients 
In this study, the active pharmaceutical ingredient tacrolimus was spray dried with 
the excipients dipalmitoylphosphatidylcholine (DPPC) and 
dipalmitoylphosphatidylglycerol (DPPG) to produce dry powder aerosol 
microparticles. DPPC and DPPG are the primary phospholipid components naturally 
present in the lungs. Lung surfactant is composed 80-90% of lipids, 70-80% and 5-
10% of which is made up of phosphatidylcholines (PC) and phosphatidylglycerols 
(PG), respectively. Approximately 60% of PC in the lungs is composed of DPPC 
(Evora, Soriano et al. 1998). Phospholipids such as DPPC and DPPG are necessary to 
support proper lung surfactant function (Meenach, Vogt et al. 2013) and help protect 
against infections and inflammation (Mansour, Wang et al. 2001). DPPC and DPPG 
are often used in lung surfactant replacement therapies and controlled drug release 
applications (Wu, Hayes et al. 2013). Phospholipids are an efficient excipient because 
they protect the structural integrity, stability, and fluidity of the drug (Alves and 
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Santana 2004). Using phospholipid excipients that are biocompatible and 
biodegradable can aid in the delivery of drugs to the lungs by improving particle and 
drug migration to the lungs because of the reduction in surface tension from the 
surfactant (Evora, Soriano et al. 1998). A large portion of inhaled medications fail to 
reach the deep lung, and it is suspected that phospholipid deposition on the mucosal 
surface of non-targeted lung areas will cause particles to be transported through the 
airways via surfactant spreading (Ganguly, Moolchandani et al. 2008). Phospholipid 
excipients may also cause the spray-dried particles delivered to the lungs to evade 
recognition and uptake by the immune system, increasing lung residence time 
(Meenach, Anderson et al. 2013). In addition, it has been found that the co-spray-
drying of drugs with DPPC can help reduce particle size and improve the aerodynamic 
performance. In addition, the presence of phospholipids in particles leads to an 
improvement in the respirable fine particle fraction (Hadinoto, Phanapavudhikul et al. 
2007). The chemical structures of DPPC and DPPG can be seen in Figures 5 and 6. 
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Figure 4. Schematic of tacrolimus (TAC). 
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Figure 5. Schematic of dipalmatoylphosphatidylcholine (DPPC). 
 
 
 
 
 
 
 
 
 16 
 
 
 
 
 
 
Figure 6. Schematic of dipalmitoylphosphatidylglycerol (DPPG). 
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1.5 Objectives and Hypothesis 
 
The overall objective of this research was to develop and characterize 
phospholipid-based aerosol microparticles loaded with tacrolimus for applications in 
the treatment of pulmonary arterial hypertension. The specific objectives of this 
research include: 
 
1. Synthesis and optimization of phospholipid-based aerosol microparticles 
containing tacrolimus using advanced spray drying methods.  
2. Evaluation of the physicochemical properties of the spray-dried microparticles 
including their size, morphology, drug loading, crystallinity, thermal properties, 
water content, and aerosol dispersion.  
3. In vitro evaluation of the safety and efficacy of the fully characterized TAC-loaded 
microparticles.  
  
 The development of an improved delivery method of the drug tacrolimus will 
lead to a more effective treatment method for PAH with fewer side effects. A smaller 
dose of TAC delivered directly to the lungs can be used than in the oral or intravenous 
delivery methods, which should minimize toxicity while optimizing the amount of 
drug that reaches the lungs. Targeting the delivery of tacrolimus to the lungs using 
phospholipid-based dry powder aerosol microparticles will result in increased 
localized drug concentrations, improving the treatment of pulmonary arterial 
hypertension and decreasing the severity of side effects experienced by patients. If 
delivering dry powder formulated TAC via a DPIs is found to be effective in treating 
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PAH, this delivery method could be applied to a multitude of other poorly water-
soluble drugs with toxic side effects that are used to treat pulmonary diseases. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
2.1 Materials 
Synthetic dipalmitoylphosphatidylcholine (DPPC, Molecular Weight: 734.05 
g/mol, >99% purity) and dipalmitoylphosphatidylglycerol (DPPG, Molecular Weight: 
744.96 g/mol, >99% purity) were obtained from Avanti Polar Lipids (Alabaster, AL, 
USA). Tacrolimus (TAC, Molecular Weight: 804.02) was obtained from LC 
Laboratories (Woburn, MA, USA). 2-Propanol (HPLC grade, 99.9% purity), 
Hydranal®-Coulomat, methanol (anhydrous, 99.8% purity), and acetonitrile (HPLC 
grade, ≥ 99.9 % purity) were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Ultra-high purity (UHP) nitrogen gas was obtained from Airgas (Radnor Township, 
PA, USA). Extra pure phosphoric acid (85% pure in water) was obtained from Thermo 
Fisher Scientific (Waltham, MA). A549 cells were obtained from ATCC (Manassas, 
VA, USA). Sodium pyruvate was obtained from Fisher Scientific. Dulbecco’s 
Modified Eagle Medium (DMEM), Pen-Strep, and Fungizone® were obtained from 
Life Technologies (Norwalk, CT, USA). Sodium acetate (1 M, pH 5), Triton X-100, 
and dimethyl sulfoxide (DMSO) were obtained from Wilkem Scientific (Pawtucket, 
RI, USA). Fetal bovine serum (FBS) was obtained from Atlanta Biologics (Flowery 
Branch, GA, USA). P-nitrophenyl (pNpp) was obtained from MP Biomedicals (Santa 
Ana, CA, USA). 
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2.2 Preparation of Spray-Dried Microparticles 
Advanced spray drying of tacrolimus and DPPC/DPPG particles was 
performed using a B-290 Büchi Mini Spray Dryer (from Büchi Labortechnik AG, 
Switzerland) in closed mode. UHP dry nitrogen was used as the drying gas and the 
spray-dried (SD) particles were collected in a sample collector. A nozzle with a 
diameter of 0.7 mm was used. The feed solutions were prepared by dissolving DPPC 
and DPPG in a 3:1 molar ratio with varying amounts of tacrolimus, including 0, 25, 
50, 75 and 100 mol% TAC to the total amount of DPPC/DPPG in isopropanol to form 
a dilute solution of 0.5% w/v. The composition of each feed solution can be seen in 
Table 1. The spray drying conditions used during particle formation were a pump rate 
of 100%, aspiration rate of 100%, and inlet temperature of 100ºC. All spray-dried 
powders were stored in small glass vials sealed with parafilm in desiccators with 
DrieriteTM desiccant at -20°C under ambient pressure. 
 
2.3 Scanning Electron Microscopy (SEM) 
The shape and surface morphology of the spray-dried particles was evaluated 
via scanning electron microscopy (SEM) using a Zeiss SIGMA VP Field Emission 
Scanning Electron Microscope (Germany). Dry powder samples were placed on 
aluminum stubs (Ted Pella Inc., Redding, CA, USA) with double-sided adhesive 
carbon tabs and then coated with a thin film of a gold/palladium alloy using a BIO-
RAD sputter coating system at 20 µÅ for 60 seconds under argon gas. Micrographs 
were collected at several different magnifications. The size of the spray-dried particles 
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was analyzed using Image J Size Analysis software with images obtained from the 
SEM at 10x magnification. Fifty particles per sample were analyzed. 
 
2.4 Differential Scanning Calorimetry (DSC) 
Thermal analysis and phase transition measurements of the raw materials and 
spray-dried particles were carried out via differential scanning calorimetry (DSC) 
using a DSC Q10 (TA Instruments, New Castle, DE, USA). 1-2 mg of the sample was 
weighed into aluminum Tzero pans with Tzero hermetic lids, both from TA 
Instruments. The pans were sealed with Tzero Press from TA Instruments. UHP dry 
nitrogen gas was the purging gas used. The samples were exposed to heating range of 
-25 to 300 ºC at a heating scan rate of 5 ºC/min. 
 
2.5 Powder X-Ray Diffraction (PXRD) 
Powder x-ray diffraction (PXRD) patterns of raw material and particle powder 
samples were measured using a Rigaku Multiflex X-ray diffractometer (the 
Woodlands, TX, USA) with a slit-detection Cu Kα radiation source (40 kV, 44 mA, 
and λ = 1.5406 Å). The scan range was 5-45º in 2θ with a scanning rate of 2 º/min at 
ambient temperature. The sample was placed on a horizontal quartz glass sample 
holder plate.  
 
2.6 Karl Fischer (KF) Coulometric Titrations 
The water content of the raw materials and spray-dried particles was 
determined by Karl Fischer (KF) coulometric titration. The measurements were 
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performed with an 851 Titrando KF Coulometer coupled with an 803 Ti Stand 
(Metrohm Ltd., Antwerp, Belgium). Approximately 10 mg of powder was dissolved in 
a known volume of anhydrous methanol. The sample solution was then injected into 
the reaction cell containing Hydranal® and the water content was calculated from the 
resulting reading. 
 
2.7 In Vitro Aerosol Dispersion Performance by the Next Generation ImpactorTM 
(NGITM) 
The in vitro aerosol dispersion of the spray-dried microparticles was 
determined using a model 170 Next Generation ImpactorTM from MSP Corporation 
(Shoreview, MN, USA) with a USP stainless steel induction port. The NGITM was 
coupled with a Copley HCP5 vacuum pump and a Copley TPK 2000 critical flow 
controller (Copley Scientific, United Kingdom). The airflow rate was set to 60 L/min 
in order to model the airflow rate in the lung of a healthy adult (Hickey and Mansour 
2009). Glass fiber filters (55 mm, Type A/E, Pall Life Sciences, PA, USA) were 
placed into the gravimetric insert cups and weighed before and after each experiment 
to determine particle deposition on each stage. Approximately 10 mg of microparticles 
were loaded into a hydroxyproyl methylcellulose capsule (HPMC, size 3, Quali-V®, 
Qualicaps® Inc, Whitsett, NC, USA) and then placed into a dry powder inhaler 
(HandiHaler, Boehringer Ingelheim Pharmaceuticals, CT, USA). The dry powder 
inhaler was attached to a rubber mouthpiece attached to the induction port on the 
NGITM. The NGITM was operated with a 10 s delay and 10 s run time. The effective 
cutoff diameters for each stage of the NGITM were given by the manufacturer as: stage 
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1 (8.06 µm); stage 2 (4.46 µm); stage 3 (2.82 µm); stage 4 (1.66 µm); stage 5 (0.94 
µm); stage 6 (0.55 µm); and stage 7 (0.34 µm). The mass median aerodynamic 
diameter (MMAD) and geometric standard deviation (GSD) were calculated using a 
Mathematica® program written by Dr. Warren Finlay (Finlay 2001). The fine particle 
dose (FPD), fine particle fraction (FPF), respirable fraction (RF), and emitted dose 
(ED) were calculated using the following equations:  
 𝐹𝑃𝐷 = 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑜𝑛 𝑆𝑡𝑎𝑔𝑒𝑠 2 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 7 
 
𝐹𝑃𝐹 =  𝐹𝑃𝐷𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑃𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑀𝑎𝑠𝑠 𝐿𝑜𝑎𝑑𝑒𝑑 𝑖𝑛𝑡𝑜 𝐶𝑎𝑝𝑠𝑢𝑙𝑒𝑠 𝑥 100% 
 
𝑅𝐹 =  𝐹𝑃𝐷𝑇𝑜𝑡𝑎𝑙 𝑃𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑀𝑎𝑠𝑠 𝑜𝑛 𝑎𝑙𝑙 𝑆𝑡𝑎𝑔𝑒𝑠  𝑥 100% 
 
𝐸𝐷 =  𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑀𝑎𝑠𝑠 𝑖𝑛 𝐶𝑎𝑝𝑠𝑢𝑙𝑒𝑠 − 𝐹𝑖𝑛𝑎𝑙 𝑀𝑎𝑠𝑠 𝑅𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝑖𝑛  𝐶𝑎𝑝𝑠𝑢𝑙𝑒𝑠𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑀𝑎𝑠𝑠 𝑖𝑛 𝐶𝑎𝑝𝑠𝑢𝑙𝑒𝑠  𝑥 100% 
 
2.8 In Vitro Dose-Response Analysis 
A549 lung adenocarcinoma cells were cultured in 75 cm2 Biolite cell culture 
flasks (Fisher Scientific) with media consisting of DMEM supplemented with 10% 
(v/v) FBS, Pen-Strep (100 U/mL penicillin, 100 µg/mL streptomycin), Fungizone® 
(0.5 µg amphotericin, B, 0.41 µg/mL sodium deoxycholate), and 1 mM sodium 
pyruvate. The cells were cultured at 37ºC and 5% CO2 in a humidified incubator. The 
A549 cells were seeded in two 96 well plates (Celltreat Scientific, Shirley, MA, USA) 
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at 100 µL/well. On day two, the cells were dosed with dilutions of TAC ranging from 
0.00001 to 10 µM of a 20,000 µM stock solution of raw TAC in DMSO. 0.1% (v/v) of 
DMSO was used in each dilution to aid in TAC solubility in media. The control for 
the calculations was 0 µM TAC in 0.1 % (v/v) DMSO. 100 µL of the dilutions were 
added to each well (n = 8). At 48 and 72 hours after drug exposure, viability of the 
cells was assessed using the acid phosphatase assay. A pNpp solution (sodium acetate, 
1% Triton X-100, and pNpp) was added to each well and the plate was then incubated 
at 37°C and 5% CO2 for two hours. The absorbance was measured at 405 nm with a 
Cytation 3 plate reader (BioTek, Winooski, VT, USA). Relative viability was 
calculated using the following equation: 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 % =  𝑆𝑎𝑚𝑝𝑙𝑒 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦  𝑥 100% 
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CHAPTER 3 
 
RESULTS AND DISCUSSION 
 
 The described study involved the physicochemical and in vitro characterization 
of tacrolimus-loaded DPPC/DPPG particles produced via spray drying. Optimization 
and design resulted in the formulation of several practical particle systems, which 
included four systems loaded to tacrolimus (25, 50, 50, and 100 mole% TAC) and one 
without (pure phospholipids). This study strived to determine the effects on the 
presence of differing TAC amounts on the particle formulations. The size, 
morphology, thermal stability and crystallinity, water content, aerodynamic dispersion 
performance, and in vitro effects on pulmonary cells were evaluated.  
 
3.1 Size and Morphology of Spray-Dried Microparticles  
 The formulated particles and their morphologies were analyzed using SEM 
micrographs, as seen in Figure 7. The geometric diameter of the particles is displayed 
in Table 1 and was determined using Image J software. 0TAC particles were 
agglomerated and as a result their diameter was immeasurable. 25TAC and 75TAC 
particles were rounder and smoother than 0TAC with some agglomeration and 
sintering between particles. 50TAC particles were spherical, smooth, and uniformly 
sized. 100TAC particles were round and smooth, but not uniformly sized. The size of 
all measurable particles was between 1.20 to 2.83 µm in size as seen in Table 1. 
50TAC particles were the largest and 100TAC particles were the smallest. All 
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particles were within the range for optimal lung deposition in children and adults 
(Meenach 2014). The particles exhibited an ideal size range (approximately 1 µm) for 
ensuring targeted delivery to specific regions of the lung. In particular, the geometric 
diameters indicate that the described microparticles are capable of delivering a 
therapeutic payload to the deep lung (Sung, Pulliam et al. 2007), which is necessary 
for the treatment of pulmonary arterial hypertension. 
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Figure 7. Representative SEM micrographs of spray-dried phospholipid-based 
microparticles: (a) 0TAC; (b) 25TAC; (c) 50TAC; (d) 75TAC; (e) 100TAC, where the 
number indicates the mole% of TAC in each system. Magnification = 10,000x. Scale 
bar = 5 µm. 
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Table 1. Systems of spray-dried phospholipid-based particles and their corresponding 
mole % of tacrolimus (TAC), dipalmitoylphosphatidylcholine (DPPC), and 
dipalmitoylphosphatidylglycerol (DPPG), outlet temperature from the spray dryer, 
geometric diameter, and water content. 
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3.2 Thermal Analysis of Spray-Dried Microparticles 
 DSC studies were performed on the raw materials prior to spray drying (TAC, 
DPPC, DPPG) and spray-dried formulated microparticles (0TAC, 25TAC, 50TAC, 
75TAC, and 100TAC) to determine their thermal behavior and melting points, as seen 
in Figure 8. An endothermic peak is evident at 129°C for raw tacrolimus (TAC), 
signifying its melting point. The endothermic peak signifying the TAC melting point 
is not present in the thermograms of the spray-dried particles due to the transition of 
TAC from crystalline to amorphous forms during the spray drying process. Raw 
DPPC and DPPG exhibited a characteristic bilayer main phase transition phase at 
71°C and 79°C. A bilayer main phase transition was also seen in the spray-dried 
microparticles at approximately 76°C, becoming less significant with increasing drug 
concentration due to the DPPC content.  
 The formulated microparticles were spray dried at an inlet temperature of 
100°C at a pump rate of 100% (the highest possible for the described system). As a 
result, the outlet temperatures of the spray drying process for the microparticles ranged 
from 42 to 45°C, as seen in Table 1. These outlet temperatures are below the phase 
transition temperatures as indicated in the DSC thermograms, therefore the spray 
drying temperatures do not negatively impact the formation of the microparticles. The 
stability microparticles at different storage conditions such as room temperature 
(22°C), refrigeration (4°C), and freezing (-20°C) is likely since there are no 
measurable DSC transition peaks present in the data. This is also true at the treatment 
condition (e.g. body temperature at 37°C). 
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Figure 8. DSC thermograms of spray-dried microparticles of varying compositions 
and their corresponding raw materials (DPPG, DPPC, and TAC). 
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3.3 Crystallinity Analysis of Spray-Dried Tacrolimus Microparticles 
X-ray powder diffractograms were collected for the raw pre-spray-dried 
components (TAC, DPPC, DPPG) and spray-dried microparticles (0TAC, 25TAC, 
50TAC, 75TAC, and 100TAC) as shown in Figure 9. Strong peaks are seen in raw 
TAC between 20 and 25° 2θ indicating the crystallinity of the material prior to the 
spray drying process. Raw DPPC exhibited a strong broad peak at 21° 2θ, which 
corresponds to the presence of the phospholipid bilayer structure (Alves and Santana 
2004). Raw DPPG showed a cluster of peaks between 18 and 25° 2θ. The spray-dried 
particles show decreasing peak intensities at 22° 2θ with increasing mole percentage 
of TAC. The peaks corresponding to raw DPPG were not noticeable in the spray-dried 
formulations, likely due to their limited presence in comparison to raw DPPC, which 
has a strong peak signal. 0TAC and 25TAC exhibited the most evident peaks of the 
spray-dried particles at 22° 2θ, indicative of the presence of phospholipid bilayer 
structures within the particles. The lack of significant peaks in the 50TAC, 75TAC, 
and 100TAC particles is likely due to the lower mole percentage of the phospholipids 
and reveals that the TAC present in the spray-dried particles is amorphous and has 
limited bilayer formation. Amorphous solids are more soluble and have higher 
dissolution rates than crystalline solids (Alves and Santana 2004). 
PXRD and DSC analysis indicate that the spray-dried phospholipid TAC-
loaded microparticles display the characteristics of particles with a lipid bilayer 
structure (likely multilamellar) owing to the signature peaks in XRD analysis and 
bilayer phase transition values in the DSC thermograms (Mansour, Wang et al. 2001, 
Mansour and Zografi 2007).  
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3.4 Water Content 
 The residual water content in the spray-dried microparticles can be seen in 
Table 1. The water content in the microparticles ranged from 4 to 10%. It was the 
highest in 0TAC particles, at 10.01 ± 3.29% and lowest in the 100TAC particles, at 
4.15 ± 1.50%. The remaining formulations had 6-7% residual water, similar to 
previously reported results (Meenach, Vogt et al. 2013) and within the range of other 
microparticles in our group (results not published). Low water content in inhalable dry 
powders is essential for aerosol dispersion properties because it reduces agglomeration 
(Meenach, Anderson et al. 2013). High water content in aerosol powders and drug 
formulations can also reduce stability due to the propensity of amorphous powders to 
recrystallize in aqueous conditions (Wu, Hayes et al. 2013). 
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Figure 9. X-ray powder diffractograms of spray-dried microparticles with varying 
compositions and their corresponding raw materials. 
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3.5 In Vitro Aerosol Dispersion Analysis 
The most important factor influencing the deposition of particulates to the 
lungs are the aerodynamic properties of the therapeutic system (Hickey and Mansour 
2009). The in vitro aerosol dispersion performance properties of the microparticles 
were evaluated using an NGITM coupled with a DPI device and can be seen in Figure 
10 and Table 2. Figure 10 demonstrates the actual aerosol dispersion performance of 
the formulated dry powder microparticles by showing the mass fraction of particles on 
each NGITM stage. The mass mean aerodynamic diameters (MMAD) of the particles 
were 4.0 ± 0.6 µm for 0TAC, 9.1 ± 2.2 µm for 25TAC, 8.7 ± 5.2 µm for 50TAC, 4.1 ± 
0.7 µm for 75TAC, and 6.0 ± 1.8 µm for 100TAC. The geometric standard deviation 
(GSD) for the spray-dried microparticles ranged from 2.1 ± 0.2 µm to 2.9 ± 0.9 µm 
and these values were similar to previously reported results (Meenach, Vogt et al. 
2013).  
The fine particle fractions (FPF) of the particles ranged from 40.6 to 74.2 %, 
the respirable fraction (RF) ranged from 35.8 to 55.7% and the emitted dose (ED) 
ranged from 88 to 100%. In addition, as indicated in Figure 10, 21-27% of 
microparticles deposited on stages 2-4 and 1-6% deposited on stages 5-7. There were 
no clear trends corresponding to the effect of amount of drug in relation to excipient 
on the aerosol dispersion properties of the microparticles. The particles with the most 
optimal aerosol performance were the 75TAC particles. Overall, aerosol dispersion 
was measurable on all of the NGITM stages and as a result these microparticles are 
predicted to deposit in the deep lung region of the human lung as well as throughout 
the upper portions of the lung as indicated by the MMAD values. 
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Figure 10. In vitro aerosol dispersion performance as mass fraction of microparticles 
deposited on each stage of the Next Generation ImpactorTM (NGITM) for spray-dried 
particles containing DPPC and DPPG with varying PTX content. For Q = 60 L/min, 
the effective cutoff diameters (D50) for each NGITM impaction stage are as follows: 
stage 1 (8.06 µm), stage 2 (4.46 µm), stage 3 (2.82 µm), stage 4 (1.66 µm), stage 5 
(0.94 µm), stage 6 (0.55 µm), and stage 7 (0.34 µm). (n = 3, Average ± SD).  
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Table 2. In vitro aerosol dispersion performance using the Next Generation 
ImpactorTM for spray-dried phospholipid-based systems containing tacrolimus. 
Parameters include mass median aerodynamic diameter (MMAD), geometric standard 
deviation (GSD), fine particle fraction (FPF), respirable fraction (RF), and emitted 
dose (ED) (n = 3, Average ± SD). 
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3.6 In Vitro Dose-Response Analysis 
 
 The effect of raw tacrolimus on the viability of A549 cells was evaluated at 48 
and 72 hours after drug exposure and can be seen in Figures 11 and 12, respectively. 
The relative viability for the A549 cells remained steady for increasing drug 
concentrations for both the 48 and 72-hour studies, showing that TAC is not toxic to 
lung cells at concentrations ranging from 0.00001 µM to 10 µM. In greater 
concentrations, the drug does become toxic (data not shown), but drug concentration 
in the lungs would not exceed this range, particularly in the spray-dried microparticles 
(Hayes, Zwischenberger et al. 2010). Delivering TAC to the lung is not expected to 
cause cell death, minimizing potential negative side effects. 
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Figure 11. 48-hour dose-response curve for A549 cells exposed to tacrolimus. 
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Figure 12. 72-hour dose-response curve for A549 cells exposed to tacrolimus.
 40 
 
CHAPTER 4 
 
CONCLUSIONS AND FUTURE WORK 
 
4.1 Conclusions 
Dry powder aerosol microparticles containing of tacrolimus (TAC), 
dipalmitoylphosphatidylcholine (DPPC), and dipalmitoylphosphatidylglycerol 
(DPPG) were successfully formulated via spray drying and exhibited optimal 
characteristics for dry powder aerosols used for the treatment of pulmonary arterial 
hypertension. Five different formulations were made with a 3 to 1 molar ratio of 
DPPC to DPPG and varying drug concentrations (0%, 25%, 50%, 75%, and 100 mole 
% TAC). The physicochemical characteristics of the microparticles were evaluated 
prior to in vitro cellular analysis. 0TAC did not form distinguishable microparticles, 
but the remaining formulations ranged from 1.5 - 2.5 µm in size. 50TAC and 75TAC 
particles were spherical and smooth with a narrow size distribution. The 
microparticles were found to be stable in the working temperature range with no 
measurable thermal degradation. The spray drying process resulted in amorphous 
microparticles, which can improve drug solubility. Water content in the microparticles 
was low, which is essential for dry powder aerosolization and formulation stability. 
The in vitro aerosol dispersion showed that these microparticles are optimal for whole, 
and in particular, deep lung deposition for drug delivery. Dose-response analysis 
showed that the concentrations of tacrolimus that will be present in the lungs would be 
nontoxic. 
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This study successfully showed that tacrolimus-loaded microparticles can be 
produced that may reduce toxicity. These systems demonstrated the successful use of 
biocompatible phospholipids as excipients in improving aerosol dispersion and 
particle size for the targeted delivery of dry powder particles. This method can 
improve the treatment of pulmonary arterial hypertension by effectively delivering 
tacrolimus in a way that minimizes side effects, improves stability, and increases 
patient convenience.  
 
4.2 Future Work 
 Future work includes the analysis of the drug loading and encapsulation 
efficiency of tacrolimus in the spray-dried microparticles, the evaluation of impact of 
the microparticles on the transepithelial electrical resistance of Calu-3 cells, and the 
dose response of the microparticles on A549 cells. Overall, the use of DPPC and 
DPPG as excipients in spray-dried microparticles for dry powder delivery could easily 
be applied to a multitude of other poorly water-soluble drugs with toxic side effects 
that are used to treat pulmonary diseases.  
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